Eskayef Pharmaceuticals

Eskayef Pharmaceuticals Limited, established in 1990, is a prominent pharmaceutical entity in Bangladesh. Following the acquisition of SK&F, USA's operations by the Transcom Group, the company has built a reputation for delivering premium quality, world-class medicines. Operating within the Healthcare and Pharmaceuticals sectors, Eskayef Pharmaceuticals focuses on innovation and accessibility in medical treatments. The company's commitment extends to serving diverse therapeutic needs, underscoring its role as a key player in the regional and international pharmaceutical landscape.

With a workforce ranging from 1,000 - 5,000 employees, Eskayef Pharmaceuticals manages operations across 2 locations. The company generates substantial revenue, reported at $426.5M, reflecting its significant market presence and operational scale. Its product portfolio includes pharmaceuticals, drugs, bulk materials, and therapeutic drugs, alongside specialized offerings in animal health, animal nutrition, and pellets. This broad range of products demonstrates Eskayef's comprehensive approach to health and well-being, catering to both human and animal health sectors with scientifically developed solutions.

Eskayef Pharmaceuticals boasts an extensive global footprint, exporting its products to over 70 countries worldwide. This international reach is a testament to its adherence to global quality standards and its strategic vision for enhancing health outcomes globally. The company actively engages in research and development to pioneer new medicines and treatments, particularly in critical areas like oncology and hormone health. For insights into the individuals driving these advancements, you can Meet Eskayef Pharmaceuticals's team. Eskayef Pharmaceuticals is dedicated to advancing healthcare through quality, innovation, and a commitment to global well-being.